Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-05-17 09:00 3766

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-04-29 08:00 4420

Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, April 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-04-13 08:00 4015

Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma

SAN FRANCISCO and SUZHOU, China, March 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-03-31 08:00 3574

Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress

SAN FRANCISCO and SUZHOU, China, March 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-03-30 20:52 3430

Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody

SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-03-01 08:23 5647

The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Feb. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-02-23 09:22 5070

Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma

SAN FRANCISCO and SUZHOU, China, Feb. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-02-09 08:00 7871

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-02-03 12:30 8909

Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia

SAN FRANCISCO and SUZHOU, China, Jan. 19, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-01-19 08:00 6431

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab injection) as First-Line Therapy in Hepatocellular Carcinoma (HCC)

SAN FRANCISCO and SUZHOU, China, Jan. 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-01-13 08:00 5661

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-01-12 13:02 5178

Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma

SAN FRANCISCO and SUZHOU, China, Dec. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-12-28 08:00 7822

Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis

SAN FRANCISCO and SUZHOU, China, Dec. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-12-23 12:30 8473

Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer

SAN FRANCISCO and SUZHOU, China, Dec. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-12-11 09:02 6971

Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-12-08 08:00 4340

Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-11-23 18:34 9099

Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-11-23 08:00 5464

Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Ophthalmology

SAN FRANCISCO and SUZHOU, China, Nov. 16, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-11-16 08:00 5271

Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

SAN FRANCISCO and SUZHOU, China, Nov. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-11-11 08:00 7486